09/26/23 7:30 AMNasdaq : ABEO low floatAbeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis BullosaAbeona Therapeutics Inc. (Nasdaq: ABEO) today announced the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of EB-101, its investigational autologous, engineered cell therapy,RHEA-AIpositive
09/12/23 7:30 AMNasdaq : ABEO managementlow floatAbeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial OfficerAbeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Madhav Vasanthavada, Ph.D., M.B.A. to the role of Chief Commercial Officer (CCO) and Head of Business Development (BD), effective immediately. In this capacity, in addition toRHEA-AIneutral
09/07/23 7:30 AMNasdaq : ABEO conferenceslow floatAbeona Therapeutics Announces Participation in Upcoming Investor ConferencesAbeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2023: A company presentation at the H.C. Wainwright Annual Global Investment Conference onRHEA-AIneutral
08/30/23 7:30 AMNasdaq : ABEO low floatAbeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA SubmissionAbeona Therapeutics Inc. (Nasdaq: ABEO) today announced the Company’s intention to proceed with the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EB-101, its investigational autologous,RHEA-AIneutral
08/08/23 7:30 AMNasdaq : ABEO earningslow floatAbeona Therapeutics Reports Second Quarter 2023 Financial ResultsOn track for Biologics License Application (BLA) submission in third quarter of 2023 Proceeds from $25 million registered direct offering in July allow initiation of pre-commercial launch activities for EB-101 Cash on hand plus proceeds from registered direct offering projected to fund operationsRHEA-AIneutral
07/28/23 7:30 AMNasdaq : ABEO low floatAbeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has completed the submission of the briefing package to the U.S. Food and Drug Administration (FDA) for the Company’s pre-Biologics License Application (BLA) meeting in August 2023. TheRHEA-AIneutral
07/19/23 8:30 AMNasdaq : ABEO low floatAbeona Therapeutics Joins Rare Disease Company CoalitionAbeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has joined the Rare Disease Company Coalition (RDCC), an alliance of life science companies committed to discovering, developing, and delivering therapies for patients impacted by rareRHEA-AIneutral
07/07/23 8:30 AMNasdaq : ABEO offeringlow floatAbeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesAbeona Therapeutics Inc. (Nasdaq: ABEO) announced the closing of its previously announced registered direct offering for total gross proceeds of $25 million, before deducting the placement agents’ fees and other offering expenses. “Our existingRHEA-AIneutral
07/03/23 8:45 AMNasdaq : ABEO offeringlow floatAbeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesAbeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has raised $25 million at-the-market from select existing investors, primarily to fund initiation of the Company’s launch preparations in anticipation of the EB-101 Biologics LicenseRHEA-AIneutral
06/09/23 7:30 AMNasdaq : ABEO low floatAbeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it received feedback from the U.S. Food and Drug Administration (FDA) on June 8, 2023, in which the Company gained the Agency’s alignment on the data required to establish retroviral vectorRHEA-AIneutral